Skip to main content
Sharp Therapeutics Corp. logo

Sharp Therapeutics Corp. — Investor Relations & Filings

Ticker · SHRX ISIN · CA8200092077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 128 across all filing types
Latest filing 2025-06-17 Proxy Solicitation & In…
Country CA Canada
Listing TSXV SHRX

About Sharp Therapeutics Corp.

https://sharptx.com/

Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for hereditary disorders. The core business involves leveraging its proprietary Disco(tm) platform, which integrates high-speed laboratory automation with advanced computational methods, including molecular-physics and mathematical modeling, to rapidly identify small molecules that correct protein defects. This approach is designed to deliver first-choice oral medicines for genetic diseases, offering advantages over traditional biologics. Sharp focuses on monogenic diseases to utilize an accelerated and de-risked clinical development path. Current lead programs address high unmet needs in Gaucher Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C.

Recent filings

Filing Released Lang Actions
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Notice of Annual Meeting of Shareholders with detailed proxy voting instructions, record date, meeting agenda items, and reference to the management information circular. This fits the definition of Proxy Solicitation & Information Statement materials sent to shareholders to provide information and request votes for the upcoming meeting. Therefore, it is classified as PSI.
2025-06-17 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a combined Notice of Annual Meeting of Shareholders and Management Information Circular, soliciting proxies, providing details on record date, voting procedures, director elections, auditor appointment, executive compensation disclosures, corporate governance practices, etc. This aligns with Proxy Solicitation & Information Statement materials sent to shareholders in advance of a meeting. It is not the full annual report or an earnings release, but specifically the proxy disclosure document.
2025-06-17 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release titled “Sharp Therapeutics Corp. Reports First Quarter 2025 Results,” summarizing key financial and operational highlights for Q1 2025, including R&D spending increases, warrant exercises, and upcoming events. It announces the release of the company’s condensed interim consolidated financial statements and MD&A for the quarter ended March 31, 2025. This format and content match an initial quarterly financial results announcement (Earnings Release), rather than the full interim report itself or a simple notice of report publication. Q1 2025
2025-05-23 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a statutory certificate (Form 52-109FV2 – Venture Issuer Basic Certificate) accompanying the issuer’s interim financial report and MD&A under Canadian NI 52-109. It is not the interim financial statements or MD&A themselves (so not an IR), nor an announcement of a report release (RPA). It is a regulatory filing required by securities legislation but does not fit any more specific category. Thus, it falls under the general “Regulatory Filings” category (RNS).
2025-05-23 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is not the interim financial report itself but a NI 52-109 Venture Issuer Basic Certificate attesting to the review and fair presentation of interim filings. It does not contain financial statements, MD&A details, or audit findings, nor is it announcing dividend or management changes. It is a regulatory attestation form under Canadian securities rules, which does not match any specific category other than the general fallback for miscellaneous regulatory filings. Therefore, it is classified as a Regulatory Filing (RNS).
2025-05-23 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussions and Analysis” (MD&A) for the three months ended March 31, 2025 and contains management’s detailed commentary on interim financial results, operations, and outlook. It references unaudited condensed interim consolidated financial statements and provides forward-looking statements, typical of a standalone MD&A. This aligns precisely with the definition of Management Reports (MDA) rather than a full interim report (IR) or an earnings release (ER).
2025-05-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.